Anifrolumab for the treatment of cutaneous lupus erythematosus: a 10-case series.

Abstract

Anifrolumab is a monoclonal antibody that targets the type I interferon receptor subunit 1. It was approved for the treatment of systemic lupus erythematosus by the US Food and Drug Administration in 2021 and by the European Medicines Agency in 2022. Although phase III clinical trials reported a statistically significant improvement in skin lesions, anifrolumab has not yet been approved for the treatment of cutaneous lupus erythematosus. We present a case series that includes 10 patients with cutaneous lupus erythematosus who demonstrated a rapid and sustained response to anifrolumab.